25 September, 2017
(NASDAQ:SRPT) by 74.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company's stock worth $68,495,000 after buying an additional 481,890 shares during the last quarter. Granite Point Capital Management, L.p. augmented its investment by buying 39,850 shares an increase of 170.5% in the quarter. That brings the Director's holdings to $2,151,311 as reported to the SEC.
A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since September 25, 2016 and is uptrending. About 275 shares traded.
Rock Springs Capital Management Lp expanded its stake by buying 11,000 shares an increase of 5.7% as of 06/30/2017. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company's stock valued at $155,000 after acquiring an additional 2,474 shares during the period. BlackRock Inc. increased its holdings in Sarepta Therapeutics by 4,403.1% during the first quarter. Inc. now owns 3,576 shares of the biotechnology company's stock valued at $121,000 after acquiring an additional 3,166 shares during the period. Voya Investment Management LLC boosted its position in Sarepta Therapeutics by 2,786.1% during the second quarter. (NASDAQ:SRPT) recently. Shamim Ruff, SVP, Regulatory Affairs & Qual reported the sale of 9,138 shares. Following the completion of the transaction, the senior vice president now owns 27,312 shares in the company, valued at approximately $1,173,596.64. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: "Sarepta Therapeutics: Golodirsen Data Is A Gamechanger" published on September 08, 2017 as well as Seekingalpha.com's news article titled: "Sarepta Therapeutics' (SRPT) CEO Douglas Ingram Presents at Morgan Stanley ..." with publication date: September 13, 2017. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Jennison Associates Ltd Liability Company reported 563,333 shares. The disclosure for this purchase can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 in the last 90 days.
SRPT has been the topic of several recent analyst reports.
On September 7 Credit Suisse maintained a stock rating of "Outperform" and moved up the price target to $81.00 from $58.00. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned "Perform" rating by Oppenheimer on Tuesday, April 26.
Among 26 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 19 have Buy rating, 1 Sell and 6 Hold. Royal Bank Of Canada reissued a "buy" rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. Nomura reissued a buy rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, May 23rd. Equity analyst Barclays added the stock to its research portfolio with an initial rating of "Equal-Weight". As per Wednesday, February 22, the company rating was maintained by Needham. After the latest session, which saw the stock close at a price of $46.83, SRPT sits -26.52% below its 52-week high. (NASDAQ SRPT) traded up 1.29% during trading on Wednesday, hitting $46.36. Trading volume was down 21.08% under the stocks average daily volume.
Company shares are trading at $45.77 impressively higher than $40.10, the 50 day moving average and quite a bit higher than the 200 day moving average of $34.92. Sarepta Therapeutics, Inc. The firm's market capitalization is $3.01 billion.
Sarepta Therapeutics, Inc. on 6/29/2017 reported its EPS as $-1.18 with the analysts projecting the EPS of the stock as $-1.32. For the past 5 years, the company's revenue has grown 0%, while the company's earnings per share has grown 0%. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. The business's quarterly revenue was up 350000.0% compared to the same quarter past year. While in the same Quarter Previous year, the Actual EPS was $-1.18. On average, analysts anticipate that Sarepta Therapeutics will post ($1.23) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: "Granite Point Capital Management L.P. Purchases 39,850 Shares of Sarepta Therapeutics, Inc". (NASDAQ:SRPT) in a report published on Friday morning, The Fly reports. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of worldwide trademark and copyright legislation.
